Aktis Oncology (NASDAQ:AKTS) Shares Up 5.8% – Here’s What Happened

Aktis Oncology (NASDAQ:AKTS)’s stock price rose 5.8% on Tuesday . The stock traded as high as $26.10 and last traded at $26.23. Approximately 34,422 shares changed hands during mid-day trading, a decline of 89% from the average daily volume of 304,971 shares. The stock had previously closed at $24.79.

Wall Street Analyst Weigh In

AKTS has been the subject of several research reports. Raymond James Financial initiated coverage on shares of Aktis Oncology in a research note on Monday, June 15th. They set a “strong-buy” rating and a $40.00 price objective for the company. William Blair assumed coverage on Aktis Oncology in a report on Wednesday, April 29th. They set an “outperform” rating on the stock. Weiss Ratings upgraded Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday. Finally, HC Wainwright lifted their price objective on Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $34.00.

Aktis Oncology Trading Up 6.3%

The stock’s fifty day moving average price is $20.40.

Aktis Oncology (NASDAQ:AKTS) last announced its quarterly earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share (EPS) for the quarter. The firm had revenue of $1.87 million for the quarter. On average, research analysts expect that Aktis Oncology will post -1.62 EPS for the current year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.